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Case Report of an Endovascular Repair of a Residual Type A
Dissection Using a Not CE Not FDA-Approved Najuta
Thoracic Stent Graft System
N. Mangialardi, MD, S. Ronchey, MD, A. Malaj, MD, M. Lachat, MD, E. Serrao, MD, V. Alberti, MD, and
S. Fazzini, MD
Abstract: This report describes an endovascular repair of a residual
type A dissection using a medical device that is not marked by european
conformity (CE) or Food and Drug Administration (FDA).
The patient underwent ascending aortic surgery for acute type A
dissection. The 2-year angio–computed tomography demonstrated
patency of the residual false lumen with evolution into a 6 cm aneurysm,
the extension of the dissection from the aortic arch to the aortic
bifurcation with thrombosis of the right common iliac artery. There
was no CE- or FDA-marked medical device indicated for this case or
any other acceptable therapeutic alternative.
We used the Najuta thoracic stent graft and successfully handled the
pathology in a multiple-phase treatment.
Technology is evolving with specific grafts for the ascending and
fenestrated grafts for the aortic arch. In this single case the Najuta
endograft, in spite of the periprocedural problems, was a valid thera-
peutic option.
(Medicine 94(3):e436)
Abbreviations: CE = European conformance, CFM = color-flow
mapping, COPD = chronic obstructive pulmonary disease, CT =
computed tomography, FDA = Food and Drug Administration,
OSAS = obstructive sleep apnea syndrome, PTFE =
polytetrafluoroethylene, TEVAR = thoracic endovascular aortic
repair, TIA = transient ischemic attack.
INTRODUCTION
T he close follow-up of operated-on acute type A aorticdissection survivors is important.1 The long-term mortality
rate is higher than that of the normal population and the out-
comes may serve as a benchmark for catheter-based (percuta-
neous, endovascular) and hybrid treatment modalities.
We report the treatment of a residual type A dissection
using a ‘‘custom-made’’ fenestrated endograft. In this case all
companies that commercialize custom-made endografts in EU
refused, for different reasons, the production of an adequate
endoprosthesys. The comorbidities of the patient did not allow
us to attempt any other way of treatment and so we decided to
ask Kawasumi Laboratories in Tokyo, Japan, for a custom-
made device.
Kawasumi Laboratories develop and produce the Najuta
endograft system.2 These grafts are approved by the authority
under applicable laws in Japan, but have no European con-
formance (CE) or Food and Drug Administration (FDA)
approval. After receiving the necessary permissions, we
handled the pathology in a multiple-phase treatment, using
the ‘‘Najuta’’ stent graft. We think by reporting this case,
we are adding another element in the large field, and not just
a chapter, of the aortic arch pathologies and their treatment.
MATERIALS AND METHODS
A 57-year-old Jehovah’s Witness gentleman was hospital-
ized in 2011 in another facility for acute type A dissection and
underwent replacement of the ascending aorta from the sino-
tubular ridge to the origin of the innominate artery with a
Dacron tube graft followed by pacemaker implantation. A
computed tomography (CT) angiography exam demonstrated
the patency of the false lumen, the extension of the dissection to
the aortic arch, descending aorta, and aortic bifurcation with
thrombosis of the right common iliac artery. At that time the
cardiac surgeon decided for a medical treatment of the
residual dissection.
On July 2013 the patient came under our observation with a
CT control demonstrating the evolution into a 6 cm arch aneur-
ysm of the false lumen. The celiac trunk and the superior
mesenteric and right renal arteries were perfused by the true
lumen; the left renal artery was perfused by the false lumen
(Figure 1A).
The patient’s comorbidities (severe chronic obstructive
pulmonary disease, obstructive sleep apnea syndrome, obesity,
prior sternotomy, and hypertension) made even more high risk
an already technically complex surgical reoperation to replace
the aortic arch and the descending thoracic aorta. He was
classified as an ASA IV patient. We decided to treat his
pathology in an endovascular fashion with a ‘‘custom-made’’
fenestrated endograft.
We contacted the companies that owned CE- or FDA-
marked devices for a fenestrated custom-made device but they
refused for different reasons: limited clinical access for their
devices to a small group of physicians as they were gaining
experience with their grafts and developing an understanding of
the patients who may benefit from their use or because it was
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impossible to manufacture a specific graft for this case. At
present there is no other CE-marked endovascular device
compatible with the indications of the case or any other
FDA-marked device.
We contacted Kawasumi Laboratories in Tokyo, Japan,
and asked them to consider the treatment of this patient with the
Najuta endograft system (Figure 1B).
The Najuta endograft system is designed for thoracic
aneurysm repair and has been developed at the Tokyo Medical
University. It is a semi–custom-made stent graft having 950
patterns of 3-dimensional structures for thoracic aortic aneur-
ysm, which enables to provide a suitable stent graft matching
with a patient’s anatomy of the aorta by applying detailed image
analysis. The basic architecture of the Najuta system includes a
rigid graft column structure that apposes the curvature of the
aorta to prevent endograft migration as well as postoperative
endoleaks. It has a precurved shape, which is critical for
enhancing the stability of the endograft in the aortic arch (Figure
1C). Z-stent elements are connected with longitudinal support
struts and covered with polytetrafluoroethylene (PTFE). The
strategic location of these struts is designed to allow the stent
position alignment to adjust with the straight portion of the
aorta. Because the PTFE graft material is sutured to the stent
framework at both ends of the endograft only, even if the stent is
deformed or kinked due to tortuous anatomy, the PTFE will be
able to expand to its diameter, thereby maintaining the luminal
area. It requires fewer suturing between Z-stent and graft,
because the connecting struts support the shape of precurved
skeletons. This device does not have a high radial force.3,4
‘‘Najuta’’ stent grafts are approved by the authority under
applicable laws in Japan and are not approved for aortic
dissection, but in this case they were used to treat a residual
type A dissection. Informed consent from the patient was
acquired in which the description of the medical device, the
lack of the CE marking, the reasons for which the patient was
not a candidate for the traditional therapeutic treatment, infor-
mation on potential adverse events, and the absence of similar
therapeutic alternatives were clearly spelled out.
The stent graft studied for the patient deviated from a
‘‘Najuta’’ stent grafts; it had a single fenestration at the center,
which was one of the differences when compared with the
normal design.
PROCEDURE
The procedure was performed under general anesthesia.
The left femoral artery was exposed and used as the access
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FIGURE 1. (A) Volume rendering of the residual type A dissection; (B) Najuta endograft; (C) precurved shape of the Najuta endograft;
(D) reconstruction of the final angiography control.
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vessel and percutaneous access was performed to the
right brachial artery. We used a 24F Gore DrySeal (W.L. Gore
& Associates, Flagstaff, AZ) introducer sheath at the left
common femoral artery and a 7F Cook Flexor 55 cm (Cook
Incorporated, Bloomington, IN) introducer sheath at the right
brachial artery.
From the brachial artery, with a Bern catheter (Boston
Scientific Corporation, Natick, MA) and a 0.035 Terumo
standard wire (Tokyo, Japan), we fenestrated the intimal flap
at the abdominal level to ensure an adequate left renal artery
perfusion after the coverage of the proximal entry tear, and then
we pulled downward to the true lumen the Terumo standard
wire (Tokyo, Japan) promptly recuperated with an Amplatz
GooseNeck (CONVIDIEN, Plymouth, MN, US) at the left iliac
artery. We had to change the 0.035 through-and-through wire
for a 0.032, 400 cm Terumo standard wire because the Najuta
endograft was not fit for a 0.035 guidewire. In this way, using
this teleferic guide from the right brachial artery to the left
femoral artery, we introduced and released in a retrograde way
the 2 modules of the endoprosthesys, a distal tapered module 34
to 30 200 mm and a proximal one 34 200 mm. The correct
position of the device in the arch was easily obtained, thanks to a
precurved shape specifically designed for the aortic arch of the
patient; the fenestration was automatically rotated and oriented
toward the supra-aortic branches. The proximal landing zone
was about 2 cm distal to the sinotubular ridge. There is no need
for cardiac pacing during the deployment, because the graft
opens with a wind sock effect taking advantage of the cardiac
output. The final angiography confirmed the proper positioning
of the device and the absence of endoleaks, the exclusion of the
proximal entry tear, and the patency of the brachiocephalic
artery and the left carotid artery (Figure 1D); also the celiac
trunk and the superior mesenteric and right renal arteries were
well perfused by the true lumen; the left renal artery was
perfused by the false lumen via the fenestration at the abdominal
level.
One week after the procedure, the patient presented recur-
rent transient ischemic attacks (TIAs) with right arm impair-
ment and speech disturbances. A left common carotid dissection
was detected by color-flow mapping and confirmed by CT
sequences. The angio-CT showed also an asymptomatic prox-
imal infolding of the endograft causing a type 1A endoleak
(Figure 2A). So we proceeded with the second surgery step. The
left femoral artery was easily reexposed and the true lumen was
regained. At that time we did not have disponibility of an
adequate aortic stent; therefore, the proximal infolding of the
endograft was treated by simple angioplasty inflating a Coda
Balloon 40 mm (Cook Incorporated) (Figure 2B). The left
common carotid artery was exposed and, in a retrograde
fashion, a Carotid WALLSTENT (Boston Scientific Corpor-
ation) was released at the origin of the left common carotid
artery. Angiography demonstrated the optimal position of the
stent and no residual dissection of the left carotid. The waspro-
cedure was successful and the patient did not experience further
TIA, but the angio-CT control revealed a residual proximal leak
(Figure 2C).
One month later the patient returned for the third surgery
step, referring also left arm claudication. Percutaneous access
was performed to the left femoral artery and the true lumen was
regained. We introduced and released an aortic stent, Jotec
‘‘double flared’’ 32 to 70 mm (Hechingen, Germany), at the
proximal landing zone (Figure 3A) of the Najuta endograft.
Angiography demonstrated the optimal position of the stent, no
residual infolding, and the patency of both coronary ostia. The
left femoral artery puncture site was sutured using 2 Perclose
ProGlide systems (Abbott Vascular Inc, Redwood City, CA).
Then we performed the left carotid-axillary artery bypass
using a 7 mm ringed eparinated polytetrafluoroethylene
(ePTFE) prosthesis tunneled under the clavicle and the occlu-
sion of the origin of the left subclavian artery with an Amplatzer
vascular plug (St. Jude Medical, Plymouth, MN).
We decided to perform a carotid-axillary bypass5 and not
the traditional carotid subclavian bypass due to the habitus of
the patient and to avoid complications with the lymphatic
channels and nerves more commonly exposed to lesions after
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FIGURE 2. (A) Angio-CT documenting the proximal infolding of
the endograft and the left common carotid dissection; (B) angio-
plasty of the proximal infolding and retrograde angiography of
the dissected left common carotid; (C) angio-CT documenting the
residual proximal leak and no residual dissection of the left
common carotid. CT¼computed tomography.
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a supraclavicular exposure. Final angio-CT, performed 1 month
later, documented the good position of all the endografts and no
residual infolding (Figure 3B–D).
DISCUSSION
Thoracic endovascular aortic repair (TEVAR) has been
established as the preferential therapeutic modality for the
treatment of intact aneurysms of the descending thoracic aorta.6
Its application has also gained a wide acceptance for the
treatment of acute thoracic aortic pathologies.7
But endografting in the aortic arch is associated with a
higher morbidity and mortality than in the descending aorta
pathologies. Recently endovascular debranching of the aortic
arch with chimney stents has provided a minimally invasive
alternative to open surgery with readily available devices.8
Most of the zone 0 intervention group still requires a
thoracotomy and also the current choice of treatment of the
ascending aorta is open graft replacement with or without aortic
valve replacement, but approximately 20% of patients are
considered unfit for open surgery.9 In the past few years, there
has been a growing interest in the use of endografts in the
ascending aorta.10 However, the biomechanical challenges of
the ascending aorta remain formidable and the durability of
endovascular repair in this territory is unknown. The ascending
aorta is constantly subjected to large fluid and tissue stresses
that are transmitted from the left ventricle. The short aortic
length and the size discrepancy between proximal and distal
segments create further challenges for designing devices that
conform to its curvature while withstanding migratory forces.
The biomechanical displacement of the ascending aorta is
significantly greater than the arch and descending thoracic
aorta, with an associated high rotational component. There is
considerable risk of endograft migration, infolding, endoleak, or
graft material failure. Iliopoulos et al11 found that wall stresses
were greater in the circumferential rather than longitudinal
direction in ascending aortic aneurysms. This may also explain
why ascending aortic dissection is a common result of a
circumferential tear in the intimal layer.
Brain injury after TEVAR is a major complication and
most often associated with the underlying pathology or exces-
sive device manipulation within the arch.12,13 Spinal cord injury
can occur immediately after TEVAR or be delayed, requiring
clinical and neurological surveillance.14 Retrograde aortic dis-
section may also occur, but in this case it was impossible due to
the presence of the Dacron tube graft replacing the ascending
aorta.
Stent graft–induced new entry has been increasingly
observed after TEVAR of aortic dissection15 and the use of
tapered stent grafts is of a great help to prevent them.
In this case we had no possibility to implant a CE- or FDA-
approved stent graft and the general conditions of the patient
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FIGURE 3. (A) Angio-CT documenting the evolution of the proximal infolding; (B) angio-CT documenting the resolution of the proximal
infolding by the well-expanded Jotec stent; (C) final volume rendering of the arch; (D) final volume rendering of the aorta. CT¼computed
tomography.
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and the refusal of any kind of blood transfusion did not permit a
new open procedure to replace the aortic arch and the descend-
ing aorta. So we considered the treatment with the Najuta
thoracic stent graft.
In this single case the Najuta endograft, in spite of the
periprocedural problems, was a valid therapeutic option.
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